|
| 36481176 | Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2023 |
| 37623017 | Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma. | Curr Oncol | 2023 |
| 37651261 | Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). | Clin Cancer Res | 2023 |
| 37563779 | Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. | J Natl Cancer Inst | 2023 |
| 37192435 | Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. | J Clin Oncol | 2023 |
| 37414620 | Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. | Clin Genitourin Cancer | 2023 |
| 36980699 | The Potential Revolution of Cancer Treatment with CRISPR Technology. | Cancers (Basel) | 2023 |
| 37196065 | Clonally expanded, thyrotoxic effector CD8<sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. | Sci Transl Med | 2023 |
| 34597472 | Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. | BJU Int | 2022 |
| 35461012 | Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. | Eur J Cancer | 2022 |
| 35817515 | Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. | J Immunol | 2022 |
| 35388003 | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. | Nat Commun | 2022 |
| 35778337 | Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2022 |
| 36155169 | Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2022 |
| 35115362 | Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. | J Immunother Cancer | 2022 |
| 35029306 | Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. | Br J Clin Pharmacol | 2022 |
| 35330111 | Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers. | Life (Basel) | 2022 |
| 35199588 | Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis. | Thyroid | 2022 |
| 34866018 | Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. | Clin Genitourin Cancer | 2022 |
| 35078711 | Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. | Clin Genitourin Cancer | 2022 |
| 34784056 | Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. | Cancer | 2022 |
| 34748398 | Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. | JCO Oncol Pract | 2022 |
| 32361873 | VEGF inhibition in urothelial cancer: the past, present and future. | World J Urol | 2021 |
| 33709428 | Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. | Int J Cancer | 2021 |
| 33558159 | The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma. | Clin Genitourin Cancer | 2021 |
| 33556233 | Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. | BJU Int | 2021 |
| 33721560 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2021 |
| 35054417 | Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches. | Life (Basel) | 2021 |
| 34098977 | Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. | Radiat Oncol | 2021 |
| 34006497 | Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. | Clin Genitourin Cancer | 2021 |
| 33423945 | A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. | Eur Urol Oncol | 2021 |
| 32778476 | "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. | Urol Oncol | 2021 |
| 31537483 | Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors. | Urol Oncol | 2020 |
| 31971495 | Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. | J Urol | 2020 |
| 31753727 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2020 |
| 31718822 | Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. | Eur Urol | 2020 |
| 31829450 | Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. | Cancer | 2020 |
| 33160359 | Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE). | BMC Urol | 2020 |
| 33101774 | Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. | Oncoimmunology | 2020 |
| 32925563 | A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. | J Immunother | 2020 |
| 32430252 | Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study. | Urol Oncol | 2020 |
| 31412004 | Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. | Eur Urol Oncol | 2020 |
| 31581306 | Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. | Cancer | 2020 |
| 31520111 | Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. | World J Urol | 2020 |
| 30326032 | Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. | JAMA Oncol | 2019 |
| 29858701 | Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. | World J Urol | 2019 |
| 31318445 | To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. | Cancer | 2019 |
| 31627918 | Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Metastatic Cancer Post Solid Organ Transplantation: A Case Report and Review of the Literature. | Transplant Proc | 2019 |
| 31099684 | Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. | Am Soc Clin Oncol Educ Book | 2019 |
| 30790015 | Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma. | Cancer Immunol Immunother | 2019 |